This medicine is authorised for use in the European Union.


Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood). ‘Essential’ means that the disease has no obvious cause.

Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk’ because of their age (over 60 years), very high platelet counts or previous clotting problems.

Xagrid contains the active substance anagrelide.

This EPAR was last updated on 20/02/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Thrombocythemia, Essential
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Takeda Pharmaceuticals International AG Ireland Branch
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Block 2 Miesian Plaza
50 -58 Baggot Street Lower
Dublin 2
D02 HW68

Product information

16/02/2023 Xagrid - EMEA/H/C/000480 - IAIN/0100/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

An at-risk patient

An at-risk ET is defined by one or more of the following features:

  • >60 years of age or;
  • a platelet count >1000 x 109/l or;
  • a history of thrombohaemorrhagic events.

Assessment history

Related content

How useful was this page?

Add your rating